Generics BulletinPreviously facing the prospect of a jury trial beginning next month, Jazz Pharmaceuticals has agreed in principle to pay $145m to resolve certain allegations that its US patent-litigation settlement a
ScripEli Lilly’s blockbuster obesity and type 2 diabetes therapy, Mounjaro (tirzepatide) has made its India debut throwing down the gauntlet to rival Novo Nordisk, currently in the wings with Wegovy (injec
Generics BulletinLupin has pressed on ‘at-risk’ with the launch of the first generic version of Johnson & Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets, with litigation ongoing over
Generics BulletinLupin and Sun Pharma’s Taro have received the first US Food and Drug Administration approvals for a generic version of Johnson & Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) – a